Share This Article:
Review Paper

Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review

Full-Text HTML XML Download Download as PDF (Size:333KB) PP. 19-32
DOI: 10.4236/mc.2013.22004    4,022 Downloads   8,485 Views   Citations

ABSTRACT

Gynecologic cancers represent a significant problem worldwide. Advanced, recurrent gynecologic cancers are often refractory to chemo-therapy, so new treatment regimens are needed. Pemetrexed is a third-generation, multi-targeted antifolate that has been approved for use in non-squamous non-small cell lung cancer and malignant pleural mesothelioma in both the United States and European Union. This paper reviews the safety and efficacy of pemetrexed in gynecologic cancers, which were defined as maligancies of the ovaries (including fallopian tubes and primary peritoneum), uterine endometrium, and uterine cervix. A search of English-language literature via PubMed and American Society of Clinical Oncology proceedings was performed from database inception to June 2012. Thirteen clinical trials involving the use of pemetrexed (alone and in combination with other agents) in gynecologic cancers were identified. These were phase I and phase II trials; there were 9 studies in ovarian cancer, 1 study in endometrial cancer, and 3 studies in cervical cancer. Pemetrexed with vitamin supplementation was tolerable in all clinical trials and had activity in ovarian and cervical cancers. Therefore, it may be reasonable to further explore the use of pemetrexed in ovarian and cervical malignancies.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Miller, D. , Tai, D. , Obasaju, C. and Vergote, I. (2013) Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. Modern Chemotherapy, 2, 19-32. doi: 10.4236/mc.2013.22004.

References

[1] Karnofsky, D.A. (1968) Mechanism of action of anticancer drugs at a cellular level. CA: A Cancer Journal for Clinicians, 18, 232-234. doi:10.3322/canjclin.18.4.232
[2] Bailey, L.B. and Gregory, J.F. III (1999) Folate metabolism and requirements. Journal of Nutrition, 129, 779- 782.
[3] Goldman, I.D. and Matherly, L.H. (1985) The cellular pharmacology of methotrexate. Pharmacology & Therapeutics, 28, 77-102. doi:10.1016/0163-7258(85)90083-X
[4] Bertino, J.R. (1993) Karnofsky memorial lecture. Ode to methotrexate. Journal of Clinical Oncology, 11, 5-14.
[5] Calvert, H. (1999) An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Seminars in Oncology, 26, 3-10.
[6] Rollins, K.D. and Lindley, C. (2005) Pemetrexed: A multitargeted antifolate. Clinical Therapeutics, 27, 1343- 1382.
[7] Rustum, Y.M., Harstrick, A., Cao, S., et al. (1997) Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. Journal of Clinical Oncology, 15, 389- 400.
[8] Shih, C., Chen, V.J., Gossett, L.S., et al. (1997) LY- 231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Research, 57, 1116-1123.
[9] Taylor, E.C., Kuhnt, D., Shih, C., et al. (1992) A di- deazatetrahydrofolate analogue lacking a chiral center at C-6,N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3d] pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase. Journal of Medicinal Chemistry, 35, 4450-4454. doi:10.1021/jm00101a023
[10] Theti, D.S. and Jackman, A.L. (2004) The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clinical Cancer Research, 10, 1080-1089.
[11] Zhao, R., Babani, S., Gao, F., Liu, L. and Goldman, I.D. (2000) The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clinical Cancer Research, 6, 3687-3695.
[12] Sierra, E.E. and Goldman, I.D. (1998) Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochemical Pharmacology, 55, 1505-1512. doi:10.1016/S0006-2952(97)00673-4
[13] Wang, Y., Zhao, R. and Goldman, I.D. (2004) Characterization of a folate transporter in hela cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clinical Cancer Research, 10, 6256-6264. doi:10.1158/1078-0432.CCR-04-0645
[14] Goldman, I.D. and Zhao, R. (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Seminars in Oncology, 29, 3-17. doi:10.1016/S0093-7754(02)70040-7
[15] Zhao, R. and Goldman, I.D. (2004) Enter Alimta: A new generation antifolate. The Oncologist, 9, 242-244. doi:10.1634/theoncologist.9-3-242
[16] Ciuleanu, T., Brodowicz, T., Zielinski, C., et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study. Lancet, 374, 1432-1440.
[17] Hanna, N., Shepherd, F.A., Fossella, F.V., et al. (2004) Randomized phase III trial of pemetrexed versus do- cetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology, 22, 1589-1597. doi:10.1200/JCO.2004.08.163
[18] Paz-Ares, L., De Marinis, F., Dediu, M., et al. (2012) PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 30, Abstract LBA7507.
[19] Paz-Ares, L., De Marinis, F., Dediu, M., et al. (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase III, randomised controlled trial. Lancet Oncology, 13, 247-255. doi:10.1016/S1470-2045(12)70063-3
[20] Scagliotti, G.V., Parikh, P., von Pawel, J., et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26, 3543-3551. doi:10.1200/JCO.2007.15.0375
[21] Alimta [package insert] (2012) Eli Lilly and Company, Indianapolis.
[22] Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21, 2636-2644. doi:10.1200/JCO.2003.11.136
[23] European Medicines Agency (2011) Alimta. http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid= . 2011
[24] Scagliotti, G., Hanna, N., Fossella, F., et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. The Oncologist, 14, 253-263. doi:10.1634/theoncologist.2008-0232
[25] Scagliotti, G., Brodowicz, T., Shepherd, F.A., et al. (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in non- squamous non-small cell lung cancer. Journal of Thoracic Oncology, 6, 64-70. doi:10.1097/JTO.0b013e3181f7c6d4
[26] American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society, Atlanta.
[27] Jemal, A., Bray, F., Center, M.M., et al. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. doi:10.3322/caac.20107
[28] Bookman, M.A. (2003) Developmental chemotherapy and management of recurrent ovarian cancer. Journal of Clinical Oncology, 21, 149s-167s. doi:10.1200/JCO.2003.02.553
[29] Modesitt, S.C. and Jazaeri, A.A. (2007) Recurrent epithelial ovarian cancer: Pharmacotherapy and novel therapeutics. Expert Opinion on Pharmacotherapy, 8, 2293-2305. doi:10.1517/14656566.8.14.2293
[30] Friedlander, M., Trimble, E., Tinker, A., et al. (2011) Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer, 21, 771-775. doi:10.1097/IGC.0b013e31821bb8aa
[31] Kano, Y., Akutsu, M., Tsunoda, S., et al. (2006) Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncology Research, 16, 85-95.
[32] Tomassetti, A., Mangiarotti, F., Mazzi, M., et al. (2003) The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human alpha-folate receptor gene in ovarian carcinoma. Cancer Research, 63, 696-704.
[33] Corona, G., Giannini, F., Fabris, M., et al. (1998) Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. International Journal of Cancer, 75, 125-133. doi:10.1002/(SICI)1097-0215(19980105)75:1<125::AID-IJC19>3.0.CO;2-F
[34] Vergote, I., Calvert, H., Kania, M., et al. (2009) A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. European Journal of Cancer, 45, 1415-1423. doi:10.1016/j.ejca.2008.12.013
[35] Giovannetti, E., Mey, V., Nannizzi, S., et al. (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non- small-cell lung cancer cells. Molecular Pharmacology, 68, 110-118. doi:10.1124/mol.104.009373
[36] Tonkinson, J.L., Worzalla, J.F., Teng, C.H., et al. (1999) Cell cycle modulation by a multitargeted antifolate, LY- 231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Research, 59, 3671-3676.
[37] Hensley, M.L., Larkin, J., Fury, M., et al. (2008) A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clinical Cancer Research, 14, 6310-6316. doi:10.1158/1078-0432.CCR-08-0338
[38] Schultz, R.M. and Dempsey, J.A. (2001) Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Research, 21, 3209-3214.
[39] Papahadjopoulos, D., Allen, T.M., Gabizon, A., et al. (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences USA, 88, 11460-11464. doi:10.1073/pnas.88.24.11460
[40] Richards, D.A., Loesch, D., Vukelja, S.J., et al. (2011) Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Investigational New Drugs, 29, 963-970. doi:10.1007/s10637-010-9414-6
[41] Sehouli, J., Camara, O., Mahner, S., et al. (2010) A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 66, 861-868. doi:10.1007/s00280-009-1230-3
[42] Chambers, S.K., Chow, H.H., Janicek, M., et al. (2012) Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clinical Cancer Research, 18, 2668-2678. doi:10.1158/1078-0432.CCR-12-0261
[43] Miller, D.S., Blessing, J.A., Krasner, C.N., et al. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. Journal of Clinical Oncology, 27, 2686- 2691. doi:10.1200/JCO.2008.19.2963
[44] Pfisterer, J., Plante, M., Vergote, I., et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of Clinical Oncology, 24, 4699-4707. doi:10.1200/JCO.2006.06.0913
[45] Pignata, S., De Placido, S., Biamonte, R., et al. (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer, 6, 5. doi:10.1186/1471-2407-6-5
[46] Bacon, M., Kitchener, H., Stuart, G.C., et al. (2011) The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer. International Journal of Gynecological Cancer, 21, 746-749. doi:10.1097/IGC.0b013e31821bb446
[47] Matulonis, U.A., Horowitz, N.S., Campos, S.M., et al. (2008) Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Journal of Clinical Oncology, 26, 5761-5766. doi:10.1200/JCO.2008.17.0282
[48] Sehouli, J., Alvarez, A.M., Manouchehrpour, S., et al. (2012) A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecologic Oncology, 124, 205-209. doi:10.1016/j.ygyno.2011.09.007
[49] Hagemann, A.R., Zighelboim, I., Novetsky, A.P., et al. (2012) Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology, 30, Abstract 5013.
[50] Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2012) AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). Journal of Clinical Oncology, 30, Abstract LBA5002.
[51] Ferlay, J., Parkin, D.M. and Steliarova-Foucher, E. (2010) Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46, 765-781. doi:10.1016/j.ejca.2009.12.014
[52] Miller, D.S., Blessing, J.A., Drake, R.D., et al. (2009) A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the gynecologic oncology. Gynecologic Oncology, 115, 443-446. doi:10.1016/j.ygyno.2009.09.004
[53] Barrett, R.J., Blessing, J.A., Homesley, H.D., et al. (1993) Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. American Journal of Clinical Oncology, 16, 494-496. doi:10.1097/00000421-199312000-00007
[54] Thigpen, J.T., Blessing, J.A., Homesley, H., et al. (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 33, 68-70. doi:10.1016/0090-8258(89)90605-7
[55] Thigpen, J.T., Buchsbaum, H.J., Mangan, C., et al. (1979) Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treatment Reports, 63, 21- 27.
[56] Thigpen, J.T., Blessing, J.A., DiSaia, P.J., et al. (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 12, 1408-1414.
[57] Lincoln, S., Blessing, J.A., Lee, R.B., et al. (2003) Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 88, 277-281. doi:10.1016/S0090-8258(02)00068-9
[58] Dizon, D.S., Blessing, J.A., McMeekin, D.S., et al. (2009) Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic oncology group trial 129-P. Journal of Clinical Oncology, 27, 3104-3108. doi:10.1200/JCO.2008.20.6995
[59] Sutton, G.P., Blessing, J.A., Homesley, H.D., et al. (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer, 73, 1453-1455. doi:10.1002/1097-0142(19940301)73:5<1453::AID-CNCR2820730521>3.0.CO;2-X
[60] Thigpen, T., Vance, R.B., Balducci, L., et al. (1981) Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer, 48, 658- 665. doi:10.1002/1097-0142(19810715)48:1+<658::AID-CNCR2820481334>3.0.CO;2-R
[61] Broun, G.O., Blessing, J.A., Eddy, G.L., et al. (1993) A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. American Journal of Clinical Oncology, 16, 18-21. doi:10.1097/00000421-199302000-00005
[62] Bertino, J.R., Waud, W.R., Parker, W.B., et al. (2011) Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biology & Therapy, 11, 627-632. doi:10.4161/cbt.11.7.14948
[63] Lu, Y. and Low, P.S. (2003) Immunotherapy of folate receptor-expressing tumors: Review of recent advances and future prospects. Journal of Controlled Release, 91, 17-29. doi:10.1016/S0168-3659(03)00215-3
[64] Lorusso, D., Ferrandina, G., Pignata, S., et al. (2010) Evaluation of pemetrexed (Alimta, LY231514) as secondline chemotherapy in persistent or recurrent carcinoma of the cervix: The CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Annals of Oncology, 21, 61-66. doi:10.1093/annonc/mdp266
[65] Goedhals, L., van Wiyk, A.L., Smith, B.L., et al. (2006) Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. International Journal of Gynecological Cancer, 16, 1172-1178. doi:10.1111/j.1525-1438.2006.00451.x
[66] Miller, D.S., Blessing, J.A., Bodurka, D.C., et al. (2008) Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology, 110, 65-70. doi:10.1016/j.ygyno.2008.03.009
[67] Gordon, A.N., Fleagle, J.T., Guthrie, D., et al. (2001) Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of Clinical Oncology, 19, 3312-3322.
[68] Lund, B., Hansen, O.P., Theilade, K., et al. (1994) Phase II study of gemcitabine (2’,2’-difluorodeoxycytidine) in previously treated ovarian cancer patients. Journal of the National Cancer Institute, 86, 1530-1533. doi:10.1093/jnci/86.20.1530
[69] Shapiro, J.D., Millward, M.J., Rischin, D., et al. (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecologic Oncology, 63, 89-93. doi:10.1006/gyno.1996.0284
[70] Burger, R.A., Brady, M.F., Bookman, M.A., et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 2473-2483. doi:10.1056/NEJMoa1104390
[71] Perren, T.J., Swart, A.M., Pfisterer, J., et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 2484-2496. doi:10.1056/NEJMoa1103799
[72] Ferrara, N., Hillan, K.J., Gerber, H.P., et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 3, 391-400. doi:10.1038/nrd1381
[73] Sato, S. and Itamochi, H. (2012) Bevacizumab and ovarian cancer. Current Opinion in Obstetrics and Gynecology, 24, 8-13. doi:10.1097/GCO.0b013e32834daeed
[74] Eisenhauer, E.L., Salani, R. and Copeland, L.J. (2012) Epithelial ovarian cancer. In: Di Saia, P.J. and Creasman, W.T., Eds., Clinical Gynecologic Oncology, 8th Edition, Elsevier Saunders, Philadelphia, 285-328. doi:10.1016/B978-0-323-07419-3.00011-4
[75] Mei, L., Chen, H., Wei, D.M., et al. (2010) Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews, CD007414.
[76] Pfisterer, J., Berek, J.S., Casado, A., et al. (2011) Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial. Journal of Clinical Oncology, 29, Abstract LBA5002.
[77] Vergote, I.B., Joly, F., Katsaros, D., et al. (2012) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. Journal of Clinical Oncology, 30, Abstract LBA5000.
[78] Markman, M., Liu, P.Y., Moon, J., et al. (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase III trial. Gynecologic Oncology, 114, 195-198. doi:10.1016/j.ygyno.2009.04.012
[79] Women’s Cancer Network (2013) Gynecologic Oncology Group (GOG) trials. http://www.wcn.org/research/ gog.html
[80] Markman, M., Bundy, B.N., Alberts, D.S., et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 1001-1007.
[81] Alberts, D.S., Liu, P.Y., Hannigan, E.V., et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335, 1950-1955. doi:10.1056/NEJM199612263352603
[82] Armstrong, D.K., Bundy, B., Wenzel, L., et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34-43. doi:10.1056/NEJMoa052985
[83] Gadducci, A., Carnino, F., Chiara, S., et al. (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord- Ovest. Gynecologic Oncology, 76, 157-162. doi:10.1006/gyno.1999.5677
[84] Hess, L.M., Ham-Hutchins, M., Herzog, T.J., et al. (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. International Journal of Gynecological Cancer, 17, 561-570. doi:10.1111/j.1525-1438.2006.00846.x
[85] Elit, L., Oliver, T.K., Covens, A., et al. (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: A systematic review with metaanalyses. Cancer, 109, 692-702. doi:10.1002/cncr.22466
[86] Jaaback, K. and Johnson, N. (2006) Intraperitoneal chemotherapy for the initial management of primary epithetlial ovarian cancer. Cochrane Database of Systematic Reviews, CD005340.
[87] National Cancer Institute (2006) Cancer Therapy Evaluation Program. NCI Clinical announcement on intraperitoneal chemotherapy in ovarian cancer. http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf
[88] Tummala, M.K., Alagarsamy, S. and McGuire, W.P. (2008) Intraperitoneal chemotherapy: Standard of care for patients with minimal residual stage III ovarian cancer? Expert Review of Anticancer Therapy, 8, 1135-1147. doi:10.1586/14737140.8.7.1135
[89] Kim, S.W., Paek, J., Nam, E.J., et al. (2010) The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology, 152, 195-199. doi:10.1016/j.ejogrb.2010.05.033
[90] Konner, J.A., Grabon, D.M., Gerst, S.R., et al. (2011) Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of Clinical Oncology, 29, 4662-4668. doi:10.1200/JCO.2011.36.1352
[91] Seamon, L.G., Carlson, M.J., Richardson, D.L., et al. (2009) Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. International Journal of Gynecological Cancer, 19, 1195-1198. doi:10.1111/IGC.0b013e3181b33d5b
[92] Smith, H.O., Moon, J., Wilczynski, S.P., et al. (2009) Southwest Oncology Group trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecologic Oncology, 114, 206-209. doi:10.1016/j.ygyno.2009.04.023
[93] Tiersten, A.D., Liu, P.Y., Smith, H.O., et al. (2009) Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009. Gynecologic Oncology, 112, 444-449. doi:10.1016/j.ygyno.2008.10.028
[94] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of Clinical Oncology, 26, 5802-5812. doi:10.1200/JCO.2008.16.4368
[95] Choy, H., Schwartzberg, L.S., Dakhil, S.R., et al. (2012) Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 30, Abstract 7002.
[96] Govindan, R., Bogart, J., Stinchcombe, T., et al. (2011) Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. Journal of Clinical Oncology, 29, 3120-3125. doi:10.1200/JCO.2010.33.4979
[97] Krug, L.M., Pass, H.I., Rusch, V.W., et al. (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cis- platin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27, 3007-3013. doi:10.1200/JCO.2008.20.3943
[98] Van Schil, P.E., Baas, P., Gaafar, R., et al. (2010) Trimodality therapy for malignant pleural mesothelioma: Results from an EORTC phase II multicentre trial. European Respiratory Journal, 36, 1362-1369. doi:10.1183/09031936.00039510
[99] Kotsakis, A.P., Heron, D.E., Kubicek, G.J., et al. (2010) Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, 28, Abstract TPS264.
[100] Monk, B.J., Sill, M.W., Burger, R.A., et al. (2009) Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study. Journal of Clinical Oncology, 27, 1069-1074. doi:10.1200/JCO.2008.18.9043
[101] Chen, C.Y., Chang, Y.L., Shih, J.Y., et al. (2011) Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. Lung Cancer, 74, 132- 138. doi:10.1016/j.lungcan.2011.01.024
[102] Sun, J.M., Han, J., Ahn, J.S., et al. (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Journal of Thoracic Oncology, 6, 1392-1399. doi:10.1097/JTO.0b013e3182208ea8
[103] Zucali, P.A., Giovannetti, E., Destro, A., et al. (2011) Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clinical Cancer Research, 17, 2581-2590. doi:10.1158/1078-0432.CCR-10-2873
[104] Kim, J.A., Sun, J.M., Lee, S.Y., et al. (2010) Genetic polymorphisms in folate metabolic pathway genes correlate with clinical outcomes in pemetrexed-treated patients. Journal of Thoracic Oncology, 5, S399.
[105] Pastoelli, D., Farina, M., Diamanti, O., et al. (2010) Germline polymorhisms of methylenetetrahydrafolate reductase (MTHFR C677T) and thymidylate synthase (TS VNTR) chemotherapy-related enzymes in patients treated with pemetrexed. Annals of Oncology, 21, 152.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.